Navigation Links
Positive Results from Phase 2 Trial of Mesoblast's Adult Stem Cell Therapy Presented at the American Heart Association Annual Meeting
Date:11/14/2011

tion of heart failure hospitalization events.  Mesoblast expects that these outcomes will be central to the primary endpoint of a Revascor™ Phase 3 trial for product regulatory approval by the United States Food and Drug Administration (FDA).

The randomized, placebo-controlled 60-patient Phase 2 trial compared the safety and efficacy of three doses of Revascor™ on top of maximal approved therapies versus maximal therapies alone in patients with moderate-to-severe congestive heart failure (CHF) defined by New York Heart Association (NYHA) class II or III status and ejection fraction below 40%.  The trial enrolled both ischemic and non-ischemic heart failure patients.  Heart failure patients with this degree of severity are known to have a high cardiac mortality over a 12-24 month period despite being on maximal approved drug and device therapies.

Treatment with MPCs was well-tolerated, with 13% of patients developing transient or persistent anti-donor antibodies which were without clinical consequence. Over a 22-month mean follow-up period, only 1/45 (2%) patients who received a single injection of Revascor™ died of cardiac causes compared with 3/15 (20%) controls (p=0.02).  In addition, MPC treatment significantly delayed the time to a first Major Adverse Cardiac Event, MACE, a composite of cardiac death, heart attack or revascularization procedures (p=0.036), and reduced the overall risk for MACE by 78% (p=0.011).

Over a mean follow-up of 18 months, 0/15 patients who received the highest dose of MPC (150M) had been hospitalized for heart failure or had died.  In contrast, 3/15 (20%) controls and 6/30 (20%) patients who received low (25M) or mid (75M) doses of MPC had either been hospitalized with heart failure or had died. This clinical improvement associated with the 150M dose was accompanied by evidence of cardiac remodelling (reduction in left ventricular end systolic volumes compared with controls
'/>"/>

SOURCE Mesoblast
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Positive Data for Nektars New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011
2. Ampio Pharmaceuticals Announces Positive Results on Ampion™ Trial for Relief of Nasal Inflammation
3. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
4. Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease
5. NeuroDerm Announces Positive Results of a Phase II Study of ND0611 Dermal Patch in Patients with Parkinsons Disease
6. Micell Technologies Announces Positive Preliminary Data from DESSOLVE I Study of MiStent® Sirolimus Drug Eluting Coronary Stent System
7. Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheims Two Investigational HCV Direct Acting Antivirals Presented at AASLD
8. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
9. Positive Phase 2b Results with Sarilumab in Rheumatoid Arthritis to be Presented as a Late-Breaking Poster at the 2011 American College of Rheumatology Annual Meeting
10. Pharmaxis Announces Major Milestone: Positive Bronchitol Opinion for Europe
11. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... 20, 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: ... for the Phase 1 study of MM-302, a ... cancer.  The results were presented today by Patricia ... session at the 2015 American Association for Cancer ... PA. Data described the safety and ...
(Date:4/20/2015)... April 20, 2015  Sigma-Aldrich Corporation (Nasdaq: ... (CR) Magazine,s list of the 100 Best Corporate ... corporate responsibility performance.  Sigma-Aldrich ranked fifth, its highest ... the list. "We are honored to ... efforts and we are extremely pleased with our ...
(Date:4/20/2015)... April 20, 2015 The preclinical contract research organization ... of drugs and safety testing of medical devices, announces that ... this week,s workshop " Drug Transporters in ADME: From the ... . The title of Dr. Hidalgo,s talk is "Modern ... session entitled "Transporter Tools of the Future." The ...
Breaking Medicine Technology:Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 2Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 3Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 4Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 5Sigma-Aldrich Named to CR Magazine's 100 Best Corporate Citizens List 2Absorption Systems Chief Scientist Ismael Hidalgo to Present at International Workshop on Drug Transporters 2
... YORK, Oct. 7, 2011 Intellect Neurosciences, Inc. (OTCBB: ... clinical-stage pipeline, and multiple licenses with major pharmaceutical companies ... interview with Dr. Daniel Chain, Ph.D., Chairman and CEO ... Dr. Chain will be discussing the state ...
... Health Solutions, Inc. (NYSE: MHS ) today ... the Silver Award for Best Practices in Health Care ... healthcare accreditation organization, during the URAC 12th Annual Quality ... ) Medco,s program was selected as one ...
Cached Medicine Technology:Intellect Neurosciences CEO to be Featured on Wall Street Reporter 2Medco Wins 2011 URAC Award for Best Practices in Health Care Consumer Empowerment and Protection 2Medco Wins 2011 URAC Award for Best Practices in Health Care Consumer Empowerment and Protection 3
(Date:4/21/2015)... 2015 CALNOC, the nation’s first nursing ... RN, FAAN, will keynote their upcoming conference – Navigating ... CA on October 26, 2015. , Dr. Burnes ... of Nurse Executives (AONE) and the first African American ... American Academy of Nursing and the National Black Nurses ...
(Date:4/21/2015)... VA (PRWEB) April 21, 2015 The Science ... as a special addition to its Lunch Break Science program. ... World of Quarks! – taking guests from the subatomic world ... form. , The Museum invites members of the community to ... the Jefferson Lab physicist. Guests will delve into the nucleus ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 Renewable energy, ... a few of the Earth Day topics USM ... and national leaders debate the affect of climate change ... variety of subject matter touching on the environmental concerns ... segments will delve into sustainable lifestyles, clean air options, ...
(Date:4/21/2015)... April 21, 2015 On Saturday, May ... the rest of his team from Georgia Eye ... to End Lupus Now, being held in Piedmont Park ... Walk proved to be the largest LFA-sponsored walk in ... effort to raise funds and awareness for lupus, an ...
(Date:4/21/2015)... 21, 2015 Invictus Medical has ... Illinois university for a second innovative technology aimed ... conducive to newborn infants’ cognitive development. , “This ... problems we have identified through extensive interviews and ... George Hutchinson, Invictus Medical’s Chief Technology Officer. “We ...
Breaking Medicine News(10 mins):Health News:Nationally Recognized Nurse Leader Linda Burnes Bolton to Present Keynote Address at CALNOC Conference 2Health News:Quarks and Forks at the Science Museum of Virginia 2Health News:USM Studios’ Programming Focuses on the Environment 2Health News:9th Annual Walk to End Lupus Now 2Health News:9th Annual Walk to End Lupus Now 3Health News:Invictus Medical Secures Rights to Second Promising New NICU Technology 2
... Drug Administration is scrutinizing the claims made by a ... to the claims made by the businessman Allan Lord, he ... The Bio-Germ Protection kits contain skin lotion, a nasal spray, ... online. ,According to the company, the lotion, which is ...
... 'Transcranial Magnetic Stimulation' (TMS) maybe the way forward ... aggressive electro-shock therapy., ,Electro-Shock Therapy or ECT is ... treat severe depression for many decades. However, it can ... and requires general anesthesia. In ECT the doctors pass ...
... can prevent the spread of melanoma// and other forms of ... a chemical found in turmeric, can block a biological pathway ... The chemical in the spices inhibits a protein called nuclear ... abnormal inflammations that can lead to a number of disorders ...
... revealed that consumption of fruits, vegetables and foods high in ... risk of heart disease. ,Western cuisines are not so ... plant foods in the diet. ,10 healthy individuals were ... to each of them. The diets were a vegetarian diet ...
... be responsible for various immune deficiency syndromes, and researchers// ... two different form of immune deficiency conditions called immunoglobulin ... ,Immune deficiency syndrome may be hereditary or acquired. Hereditary ... defects in the cells and tissues that are responsible ...
... help in the brain development of foetus and infants for ... administered to pregnant women. A new study conducted by scientists ... slow down the cognitive decline in middle-aged subjects. , ... and women) with increased levels of homocysteine. This amino acid ...
Cached Medicine News:Health News:A New Product Offering protection against anthrax 2Health News:Strong Magnetic Stimulation Can Help Treating Severe Depression 2Health News:Fibre Rich Food A Boon For Lowering Cholesterol 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: